An AFP blood test measures alpha-fetoprotein, a protein your liver produced in large amounts before you were born and normally makes only in trace quantities once you are an adult. Because that protein reappears in the bloodstream when certain liver cells and germ cells start growing abnormally, clinicians use it as a tumor marker, as a way to follow treatment, and, in a separate context, as one input into prenatal screening. A single number on its own rarely settles anything. In this article you will learn what the test actually measures, how to read your result against a reference range, which conditions push alpha-fetoprotein up, why a normal value does not rule out disease, and what researchers have recently learned about pairing this marker with others to catch liver cancer earlier.
What an AFP blood test measures
Alpha-fetoprotein is a glycoprotein, meaning a protein with sugar chains attached. During pregnancy it is made by the fetal liver and yolk sac, and it circulates at very high concentrations in fetal blood, where it appears to carry fatty acids and other molecules much the way albumin does later in life. After birth, production shuts down over the first year, and adult levels settle to a small residual amount.
That biological history is what makes the marker useful. When an adult’s alpha-fetoprotein climbs, it usually means some population of cells has switched back on a fetal program of protein production. Liver cells regenerating after injury do this to a modest degree. Liver tumor cells and certain germ cell tumors of the testis or ovary can do it far more dramatically.
One consequence of that biology is worth holding on to. Alpha-fetoprotein is not a liver-damage test in the way that enzymes are. Enzymes leak out of injured cells, so they answer the question of whether the liver is being harmed right now. Alpha-fetoprotein is actively manufactured and released, so it answers a different question: whether some group of cells has reverted to a growth program it should have retired at birth. That is why the two kinds of test can disagree, and why a clinician reads them together rather than treating one as a check on the other.
How the sample is collected
The test is a routine venous blood draw, usually from the arm, and it takes a couple of minutes. No fasting is required, and you can keep taking your usual medicines unless your clinician says otherwise. Results typically come back within a few days. If you are being monitored over time, try to have repeat draws processed by the same laboratory, because different analyzers can report slightly different values for the same sample.
AFP and its variants
Laboratories can measure total alpha-fetoprotein, and some can also measure a subfraction called AFP-L3. That subfraction is distinguished by how it binds to a plant protein in the laboratory, and a higher proportion of it tends to point toward a tumor rather than toward inflamed but non-cancerous liver tissue. AFP-L3 is not part of a standard panel everywhere, so most people will see only a single total value on their report.
Why doctors order an AFP blood test
The most common reason is surveillance in people who already have chronic liver disease. Long-standing scarring of the liver raises the risk of primary liver cancer substantially, so clinicians follow at-risk patients on a schedule rather than waiting for symptoms. If you want the wider clinical picture behind that scarring, review our guide to cirrhosis symptoms, causes, and care options.
A second reason is monitoring a known cancer. When a tumor produces alpha-fetoprotein, the level tends to fall as treatment works and to rise again if the disease returns, which makes serial measurements a useful signal of response. The National Cancer Institute makes the same general point about tumor markers as a class: repeated measurements during treatment often say more than any single reading.
A third reason is workup of a suspicious finding. If imaging shows a liver mass, or a young man has a testicular lump, alpha-fetoprotein is measured alongside other markers to help characterize what the clinical team is dealing with. In germ cell tumors it is frequently ordered together with human chorionic gonadotropin, and you can read more about that companion marker in our guide to hCG blood test results and what they indicate. Lactate dehydrogenase frequently joins the same panel as a general indicator of tissue turnover.
How to read your AFP result
Adult results are reported in nanograms per milliliter, abbreviated ng/mL. Many United States laboratories treat values below roughly 10 ng/mL as within the expected range for a non-pregnant adult, but this cutoff is not universal. Reference intervals are set locally by each laboratory from its own analyzer and its own reference population, so the range printed on your report is the one that applies to you.
Two habits make the number far more informative. First, read it next to the rest of your liver panel rather than in isolation. Second, compare it with your own previous results. A stable value that has sat just above the cutoff for years carries a very different meaning from a value that has doubled since your last visit, even if both are flagged the same way on the printout.
The table below shows how alpha-fetoprotein sits alongside the other blood tests that usually accompany it on a liver-focused order.
| Blood test | What it mainly reflects | What it adds next to AFP |
|---|---|---|
| Alpha-fetoprotein | Cells making a fetal protein again | Points toward tumor activity or active liver regeneration |
| ALT | Liver cell injury | Shows whether the liver is currently inflamed |
| AST | Injury to liver and other tissues | Helps separate liver damage from muscle sources |
| Albumin | The liver’s manufacturing capacity | Indicates how well the organ still functions |
| Total bilirubin | Waste clearance through the liver | Flags blockage or reduced processing capacity |
Each of those companions has its own interpretation rules. Check what a raised enzyme actually signals in our guide to the ALT liver enzyme and its normal range, compare it with our explanation of the AST liver enzyme test, and see how synthesis is assessed in our guide to albumin blood test results. Waste clearance is covered in our article on total bilirubin levels and what they reveal.
What high AFP levels can mean
An elevated alpha-fetoprotein reading is a prompt to investigate, not a diagnosis. Both cancerous and non-cancerous conditions can raise it, and the size of the elevation, its direction over time, and the clinical context together decide what happens next.
Primary liver cancer is the elevation clinicians most want to rule out, and our overview of liver cancer symptoms, causes, and treatments covers how that diagnosis is confirmed. Germ cell tumors of the testis or ovary are the other malignant group commonly associated with a rise. Benign causes are considerably more frequent overall, particularly ongoing viral hepatitis and the regeneration that follows any significant liver insult.
| Cause of elevation | Typical pattern over time | Usual next step |
|---|---|---|
| Primary liver cancer | Rises steadily and does not settle | Contrast imaging of the liver |
| Germ cell tumor | Often high, alongside other tumor markers | Imaging and specialist referral |
| Chronic viral hepatitis | Mildly up, moves with inflammation | Repeat testing with liver enzymes |
| Cirrhosis without tumor | Fluctuates modestly around a baseline | Continued scheduled surveillance |
| Recovery after liver injury | Rises then falls as healing finishes | Recheck after several weeks |
| Pregnancy | Expected to be high throughout | Interpreted on a pregnancy-specific scale |
Chronic viral infection deserves particular attention because it is both common and treatable. Our guides explain how to interpret hepatitis B symptoms, causes, and treatments and how the picture differs in hepatitis C infection and its treatment options.
AFP screening during pregnancy
In pregnancy, alpha-fetoprotein is measured for an entirely different purpose, and the numbers are not comparable to adult tumor-marker values. During pregnancy the protein crosses from the fetus into maternal blood, so a healthy expectant parent has a level far above any adult reference range. What matters is not the raw figure but how it compares with the average for that exact week of gestation.
The test is usually drawn between weeks sixteen and twenty-two, either alone or as part of a multi-marker screen. Results are expressed as multiples of the median, a scale that answers a single question: is this level unusually high or unusually low for this stage of pregnancy? A higher-than-expected value can suggest an opening in the developing spine or abdominal wall. A lower-than-expected value can shift the estimated likelihood of certain chromosomal conditions.
Two points prevent a great deal of unnecessary worry. First, this is a screening test, not a diagnostic one: it estimates likelihood and nothing more, and a flagged result leads to detailed ultrasound or further testing rather than to a conclusion. Second, several ordinary explanations produce an unexpected number, including a due date that is off by a week or two and a pregnancy with more than one fetus. MedlinePlus makes exactly this point in its patient guidance on the test.
The limits of AFP and when to call your doctor
The central limitation is that a substantial share of liver cancers never raise alpha-fetoprotein at all, particularly when they are small. A normal result is therefore reassuring but not conclusive, which is precisely why current surveillance practice for people with cirrhosis pairs a blood marker with imaging every six months rather than relying on either alone.
The mirror-image limitation is false alarms. Inflamed or regenerating liver tissue can push the marker up in someone who has no tumor whatsoever, which is why a single elevated reading in a person with active hepatitis is usually rechecked before anything else happens. Getting an unexpected flag on an otherwise unremarkable report is common enough that we wrote a separate guide on high blood test results when you feel completely fine.
A third limitation is subtler and shows up mostly in people who are being monitored long term. Because each laboratory calibrates its own instruments, a value measured on one analyzer is not perfectly interchangeable with a value measured on another. A modest apparent jump after a change of laboratory or insurance network can reflect the method rather than your body. If your result moves unexpectedly and your care has recently shifted between facilities, that is worth mentioning, because it may prompt a confirmatory draw rather than an immediate workup.
Contact your clinician promptly if a result is flagged and you also notice yellowing of the skin or eyes, persistent pain in the upper right abdomen, unexplained weight loss, swelling of the abdomen or legs, or a new testicular lump. Contact them without urgency, but do contact them, if a previously stable value has risen across two consecutive draws, if you have chronic liver disease and have missed scheduled surveillance, or if you simply do not understand what your report says. Other tumor markers follow similar interpretation logic, as our guides to CEA blood test results and PSA test results and their interpretation both illustrate.
Latest scientific advances
Research over the past three years has focused less on replacing alpha-fetoprotein than on surrounding it with better company. A large multicenter study published in Gastroenterology in 2025 followed more than fifteen hundred people with cirrhosis and compared the marker on its own against a combined score that blends it with age, sex, and two additional blood measurements. The combined score identified noticeably more of the cancers that would be diagnosed within the following year. What this means for you is that if your care team orders several markers at once rather than just one, they are following where the evidence has moved, not over-testing.
A 2025 review in Gastroenterology Report reached a similar conclusion from a wider angle. It described how surveillance is shifting toward risk stratification, meaning that the intensity of monitoring is matched to each person’s individual risk profile rather than applied uniformly, and it noted that combined marker scores now perform better than alpha-fetoprotein alone in the most rigorous category of validation study. The same review was candid that the larger problem is not the test but the fact that many people who should be under surveillance never receive it.
Two 2024 reviews, one in Diagnostics and one in Cancers, surveyed the newer candidates being studied: fragments of tumor DNA circulating in blood, small regulatory RNA molecules, and sugar-coating patterns on proteins. Both concluded that these approaches look promising for earlier detection but still need large prospective trials, meaning studies that enroll people first and follow them forward, before they change routine care. For now, alpha-fetoprotein remains a standard part of liver cancer surveillance, and the practical advice from all of this research is unchanged: keep to your monitoring schedule, and read each result as part of a trend rather than as a verdict.
Glossary
| Term | Definition |
|---|---|
| Alpha-fetoprotein (AFP) | A protein made abundantly before birth and only in small amounts in adults. Its return to the bloodstream can signal tumor activity or liver regeneration. |
| Tumor marker | A substance measurable in blood or tissue that can rise when cancer is present. It supports diagnosis and monitoring but does not confirm a diagnosis alone. |
| Reference range | The span of values a laboratory considers expected for a healthy population using its own equipment. Ranges differ between laboratories. |
| Surveillance | Repeated testing on a fixed schedule in people at raised risk of a disease, intended to detect it before symptoms appear. |
| Cirrhosis | Advanced scarring of the liver caused by long-term injury. It is the main risk state that leads clinicians to start liver cancer surveillance. |
| Germ cell tumor | A growth arising from the cells that form eggs or sperm, most often in the testis or ovary. Some types release alpha-fetoprotein. |
| AFP-L3 | A subfraction of alpha-fetoprotein identified by a laboratory binding technique. A higher proportion tends to favor a tumor over benign liver disease. |
| Multiples of the median (MoM) | The scale used in pregnancy screening that compares a result with the average for the same week of gestation instead of a fixed range. |
| Nanogram per milliliter (ng/mL) | The unit used to report adult alpha-fetoprotein concentration in blood. |
| Risk stratification | Sorting patients into groups by their individual likelihood of developing a condition, so monitoring can be matched to actual risk. |
Frequently asked questions
What is a normal AFP level in an adult?
Many laboratories in the United States treat an adult value below about 10 ng/mL as expected, but there is no single universal cutoff. Each laboratory establishes its own reference interval from its analyzer and its local population, so the range printed beside your result is the one that applies. If you are being followed over time, your own previous values are often more informative than the printed range, because a stable slightly-raised number means something different from a rising one.
Do normal AFP levels differ between men and women?
Outside of pregnancy, the expected adult range is essentially the same regardless of sex, and most laboratories report a single reference interval for all non-pregnant adults. Pregnancy is the one situation that changes everything, because levels then rise far above the adult range as a normal feature of gestation and are read on a completely separate scale tied to the week of pregnancy.
What AFP level indicates cancer?
No single threshold confirms cancer. Very high readings in someone with chronic liver disease raise concern and lead to imaging, but many people with liver cancer have normal or only mildly raised values, and many people with elevated values have no cancer at all. A diagnosis requires imaging and sometimes tissue sampling. The trend across repeated tests is generally more meaningful to your clinician than any one number.
Can a normal AFP result rule out liver cancer?
No. A meaningful share of liver tumors, especially small early ones, never raise this marker. That is exactly why guidelines pair blood testing with ultrasound imaging on a regular schedule for people at increased risk, rather than relying on the blood test by itself. A normal result is genuinely reassuring, but it is not a substitute for staying on your monitoring schedule.
How often should the test be repeated?
For people under surveillance because of chronic liver disease, testing alongside imaging roughly every six months is the usual pattern, though your clinician sets the interval based on your specific situation. If a result is being investigated, a repeat draw after a few weeks is common, because a transient rise from inflammation or healing often settles on its own while a concerning rise continues upward.
Can anything I do at home lower my AFP level?
There is no diet, supplement, or exercise routine that directly lowers alpha-fetoprotein, and treating the number itself is not the goal. What helps is addressing the underlying liver condition: taking prescribed antiviral treatment for hepatitis, avoiding alcohol, managing weight and blood sugar, and keeping vaccinations current. When liver inflammation settles, a mildly raised marker often drifts down as a consequence.
Sources
- MedlinePlus, National Library of Medicine — Alpha-Fetoprotein (AFP) Test — MedlinePlus Medical Test, reviewed 2025 — medlineplus.gov
- Cleveland Clinic — Alpha-Fetoprotein (AFP) Test: Procedure and Results — Cleveland Clinic Health Library, 2024 — my.clevelandclinic.org
- National Cancer Institute — Tumor Markers in Common Use — NCI Fact Sheet, reviewed 2024 — cancer.gov
- Marsh TL, Parikh ND, Roberts LR, et al. — A Phase 3 Biomarker Validation of GALAD for the Detection of Hepatocellular Carcinoma in Cirrhosis — Gastroenterology, 2025 — doi.org/10.1053/j.gastro.2024.09.008
- Polpichai N, Maneenil C, Danpanichkul P, et al. — Current and New Strategies for Hepatocellular Carcinoma Surveillance — Gastroenterology Report, 2025 — doi.org/10.1093/gastro/goaf045
- Attia AM, Rezaee-Zavareh MS, Hwang SY, et al. — Novel Biomarkers for Early Detection of Hepatocellular Carcinoma — Diagnostics, 2024 — doi.org/10.3390/diagnostics14202278
- Fares S, Wehrle CJ, Hong H, et al. — Emerging and Clinically Accepted Biomarkers for Hepatocellular Carcinoma — Cancers, 2024 — doi.org/10.3390/cancers16081453
Further reading
- Compare a second tumor marker used in gynecologic care by reading our guide to CA-125 test results and what they measure.
- Examine the enzyme that flags bile duct and bone activity in our guide to alkaline phosphatase results and their causes.
- Understand why enzyme values jump between visits by reading our analysis of liver enzyme spikes and how they are interpreted.
- Build a broader method for reading any report with our guide to reference ranges, flags, and next steps for lab results.
- Review the short-lived liver infection that can also raise markers in our guide to hepatitis A symptoms, causes, and treatment.
Understand your lab results with BloodSense
An alpha-fetoprotein value is difficult to judge alone, because its meaning depends on your liver enzymes, your medical history, and how the number has moved since your last draw. Tests such as ALT, AST, albumin, and bilirubin fill in the context that turns a flagged figure into something you can actually reason about. BloodSense reads your full report in plain language, shows where each marker sits relative to its reference range, and tracks how your values change across visits so you arrive at your appointment with informed questions rather than guesswork. It helps you understand your results; it does not diagnose, and it does not replace your doctor.
